PHAT (Phathom Pharmaceuticals) Total Liabilities : $574.16 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals Total Liabilities?

Phathom Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 was $574.16 Mil.

Phathom Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2024 ($505.00 Mil) to Jun. 2024 ($553.21 Mil) and increased from Jun. 2024 ($553.21 Mil) to Sep. 2024 ($574.16 Mil).

Phathom Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($117.28 Mil) to Dec. 2022 ($239.62 Mil) and increased from Dec. 2022 ($239.62 Mil) to Dec. 2023 ($486.60 Mil).

Phathom Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Phathom Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals Total Liabilities Chart

Phathom Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

29.22

100.84

117.28

239.62

486.60

Phathom Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															254.77	486.60	505.00	553.21	574.16

Phathom Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Phathom Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	38.781	+	(138.304	+	309.516
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	486.60

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	413.842	-	-72.759
	=	486.60

Phathom Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	65.288	+	(175.729	+	333.139
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	574.16

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	387.044	-	-187.112
	=	574.16

Phathom Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Phathom Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932

Website

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Executives

Azmi Nabulsi	officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Molly Henderson	officer: CFO and CBO	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Asit Parikh	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frank Karbe	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David A Socks	director, officer: President, CEO, Treas. & Sec.	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo	officer: VP, Chief Accounting Officer	C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse	director	5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola	director	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116